J. Safra Sarasin Holding AG Has $28.67 Million Stock Holdings in Abbott Laboratories $ABT

J. Safra Sarasin Holding AG grew its position in Abbott Laboratories (NYSE:ABT) by 1.9% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 210,754 shares of the healthcare product maker’s stock after purchasing an additional 3,904 shares during the period. J. Safra Sarasin Holding AG’s holdings in Abbott Laboratories were worth $28,665,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. ASR Vermogensbeheer N.V. boosted its stake in shares of Abbott Laboratories by 0.7% in the 2nd quarter. ASR Vermogensbeheer N.V. now owns 200,546 shares of the healthcare product maker’s stock valued at $27,275,000 after purchasing an additional 1,419 shares in the last quarter. DMKC Advisory Services LLC boosted its stake in shares of Abbott Laboratories by 88.1% in the 2nd quarter. DMKC Advisory Services LLC now owns 29,289 shares of the healthcare product maker’s stock valued at $3,984,000 after purchasing an additional 13,721 shares in the last quarter. Cliftonlarsonallen Wealth Advisors LLC boosted its stake in shares of Abbott Laboratories by 5.6% in the 2nd quarter. Cliftonlarsonallen Wealth Advisors LLC now owns 11,176 shares of the healthcare product maker’s stock valued at $1,520,000 after purchasing an additional 592 shares in the last quarter. EWA LLC acquired a new stake in shares of Abbott Laboratories in the 2nd quarter valued at $229,000. Finally, Northstar Group Inc. boosted its stake in shares of Abbott Laboratories by 121.8% in the 2nd quarter. Northstar Group Inc. now owns 15,030 shares of the healthcare product maker’s stock valued at $2,044,000 after purchasing an additional 8,255 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Activity at Abbott Laboratories

In other news, CFO Philip P. Boudreau sold 5,550 shares of the company’s stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the sale, the chief financial officer directly owned 51,003 shares of the company’s stock, valued at $6,862,453.65. This represents a 9.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.46% of the stock is currently owned by company insiders.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $133.53 on Thursday. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30. The stock has a market cap of $232.39 billion, a PE ratio of 16.73, a price-to-earnings-growth ratio of 2.54 and a beta of 0.69. The stock has a 50-day moving average of $131.63 and a 200-day moving average of $131.24. Abbott Laboratories has a one year low of $110.86 and a one year high of $141.23.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, meeting analysts’ consensus estimates of $1.26. The company had revenue of $11.14 billion during the quarter, compared to analysts’ expectations of $11.01 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.Abbott Laboratories’s revenue was up 7.4% on a year-over-year basis. During the same period in the prior year, the business posted $1.14 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, sell-side analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be paid a $0.59 dividend. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. Abbott Laboratories’s dividend payout ratio is 29.57%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on ABT shares. William Blair upgraded shares of Abbott Laboratories to a “strong-buy” rating in a research note on Thursday, July 17th. BTIG Research reduced their price target on shares of Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating on the stock in a research report on Friday, July 18th. Raymond James Financial reduced their price target on shares of Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating on the stock in a research report on Friday, July 18th. Leerink Partnrs upgraded shares of Abbott Laboratories to a “hold” rating in a research report on Monday, June 16th. Finally, The Goldman Sachs Group upped their target price on shares of Abbott Laboratories from $153.00 to $157.00 and gave the company a “buy” rating in a research report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $145.39.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.